Johnson & Johnson Reports Third Quarter Earnings and Announces Plan to Separate Orthopaedics Business

Strategic Insights -

Johnson & Johnson (JNJ) released its third quarter earnings report on October 14, 2025, announcing sales of $52.1 billion and earnings per share (EPS) of $2.10. The company's Orthopaedics business is expected to be separated, with a press release announcing the plan dated October 14, 2025.

Key Takeaways:

  • Johnson & Johnson reported third quarter sales of $52.1 billion, representing a 5% increase year-over-year.
  • Earnings per share (EPS) for the quarter were $2.10, a 7% increase from the same period in 2024.
  • The company's Orthopaedics business will be separated, with a plan announced on October 14, 2025.
  • The separation plan is expected to enhance the company's focus on its pharmaceutical and medical device businesses.
  • Johnson & Johnson's global presence is maintained, with products distributed in over 175 countries.
  • The company has been a long-standing leader in the pharmaceutical, medical device, and consumer goods industries, with a history dating back over 130 years.
  • The separation of the Orthopaedics business builds on JNJ's previous strategic moves, such as the spin-off of its Consumer segment in 2019.

Statistics:

  • Third quarter sales: $52.1 billion (5% increase year-over-year)
  • Earnings per share (EPS): $2.10 (7% increase from 2024)
  • Orthopaedics sales: $11.4 billion (12% increase year-over-year)
  • Total number of employees: approximately 137,000 (as of September 28, 2025)
  • Total number of countries where products are distributed: over 175
  • Time in operation: over 130 years
  • Andrews, N.C., marked the initial production of BOVRIL ( d) in 1887; however, no date of operation was specified.